Category Archives: Biotechnology

OLD LYME, Conn., June 2, 2022 /PRNewswire/ -- Simpson Healthcare, a leading scientific agency providing the pharmaceutical, biotechnology, medical diagnostic and device industries with a wide range of services in support of overall marketing strategies, announced today that it has successfully completed the ISO/IEC 27001 certification and its privacy information management extension ISO/IEC 27701.

Scott Algiere, Chief Executive Officer of Simpson Healthcare, commented, "ISO 27001 and ISO 27701 are globally renowned and trusted industry standards. This is an achievement for Simpson Healthcare and demonstrates our continued commitment to ensure security and privacy". This provides independent, third-party validation that we have the appropriate controls in place to mitigate risks related to the services we provide to our customers and is key to our customers upholding their own regulatory obligations. Abdullah Amin, SVP Engineering + IT Security, commented, "These certifications highlight our commitment to data privacy and information security. Our customers know that their information is secure and processed appropriately by maintaining security and compliance".

About ISO/IEC 27001

For ISO/IEC 27001 certification, the scope of Simpson Healthcare information security management system (ISMS) includes people, processes, and technology for creating and supporting their products and services. The report provides assurance to customers that Simpson Healthcare adheres to these stringent, internationally recognized security standards.

ISO/IEC 27001:2013 is one of the most widely recognized and internationally accepted information security standards, detailing best practices for the management of information security and privacy. It identifies requirements for a comprehensive Information Security Management System (ISMS) and establishes quality standards used to measure an organization's IT security controls and processes for handling and managing data.

About ISO/IEC 27701

For ISO/IEC 27701 certification, the scope of Simpson Healthcare privacy information management system (PIMS) includes alignment and incorporation of privacy best practices into people, processes, and technology for protection and management of personally identifiable information (PII).

ISO/IEC 27701:2019 is built to complement the widely-used ISO/IEC 27001 standard for information security management. It specifies requirements and provides guidance for a Privacy Information Management System (PIMS). ISO/IEC 27701 accomplishes the security and privacy integration through a framework for managing personal data that can be used by both data controllers and data processors, a key distinction for General Data Protection Regulation (GDPR) compliance.

A-LIGN, an independent and accredited third-party CPA firm, completed the assessment of Simpson Healthcare' systems and successfully validated that its controls meet the standards required for ISO/IEC 27001 certification as well as ISO/IEC 27701 extension.

About Simpson Healthcare

Simpson Healthcare is an established scientific agency that provides the pharmaceutical, biotechnology, medical diagnostic and device industries with a wide range of services in support of overall marketing strategies. The products and services provided enhance a company's value for the benefit of the stakeholders, while simultaneously disseminating new biomedical knowledge for the benefit of healthcare providers and their patients.

Simpson's high-quality, creative, strategic solutions are delivered with unparalleled customer service, and include brand strategy, KOL development, advisory boards, speaker bureaus, live/virtual speaker training, content development, interactive patient case videos, sales force training, and community live events.

Contact: Abdullah Amin, SVP Engineering + IT Security [emailprotected]

SOURCE Simpson Healthcare

Excerpt from:
Simpson Healthcare AWARDED ISO/IEC 27001:2013 & ISO/IEC 27701:2019 CERTIFICATION - PR Newswire

Nautilus Biotechnology (NASDAQ:NAUT Get Rating) is one of 42 public companies in the Analytical instruments industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to similar companies based on the strength of its dividends, analyst recommendations, risk, earnings, institutional ownership, valuation and profitability.

Insider and Institutional Ownership

47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 60.0% of shares of all Analytical instruments companies are owned by institutional investors. 13.4% of shares of all Analytical instruments companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

This table compares Nautilus Biotechnology and its rivals net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Nautilus Biotechnology and its rivals, as provided by MarketBeat.

Nautilus Biotechnology currently has a consensus price target of $8.67, suggesting a potential upside of 131.73%. As a group, Analytical instruments companies have a potential upside of 35.16%. Given Nautilus Biotechnologys stronger consensus rating and higher probable upside, research analysts plainly believe Nautilus Biotechnology is more favorable than its rivals.

Valuation & Earnings

This table compares Nautilus Biotechnology and its rivals gross revenue, earnings per share (EPS) and valuation.

Nautilus Biotechnologys rivals have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Nautilus Biotechnology rivals beat Nautilus Biotechnology on 8 of the 12 factors compared.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Head-To-Head Comparison: Nautilus Biotechnology (NAUT) and Its Peers - Defense World

The Peoples Republic of Chinas emergence as a global power is rooted in the rapid development of a sovereign innovation infrastructure, one that allows China to compete in high-technology races with the United States. Chinas build-up of its innovation infrastructure is complemented by another process: an intensifying cooperation with the Russian Federation in security, trade, energy supplies, artificial intelligence, 5G, space research, and biotechnology. Moscow and Beijing have a complicated history of interactions. Previously, China and the Soviet Union were isolated from the world market of technology, and after the Sino-Soviet relationship worsened, they were also isolated from each other. However, today, in light of deteriorating relations with the United States, strategic alignment emerges. The U.S. and the European Unions decoupling from business with China and imposing economic sanctions on Russia push the two countries to examine the potential of their strategic cooperation more closely.[1]

China and Russia are very different in terms of their innovation performance. China has an ascending trajectory and has already advanced to self-sufficient manufacturing of sophisticated intermediate goods.[2] It is well integrated into global innovation networks, while Russia is not. Since the break-up of the Soviet Union, Russia has been sliding down a descending trajectory.[3] It became a natural resource exporter heavily dependent on imports of foreign technology.

Regardless of these differences, Beijing and Moscow are actively developing a joint innovation infrastructure. The two countries declared 2020 and 2021 the Cross Years of Russian and Chinese scientific, technical, and innovation cooperation.[4] China demonstrated its ability in launching and managing large-scale projects and leads in Sino-Russian partnerships. Most of the infrastructure projects take place under the auspices of the Belt and Road Initiative.[5] For example, one of its institutes is Russia-China Investment Fund, a private equity fund established jointly by the Russian Direct Investment Fund and China Investment Corporation, which equally committed USD 2 billion.[6]

Lomonosov Moscow State University (left) and Tsinghua University Campus (right). (Adobe Stock)

The purpose of building this type of infrastructure is to accelerate Sino-Russian partnerships in science and technology and facilitate technology transfer. In 2020, the two countries announced the construction of the first Sino-Russian Innovation Complex, a joint venture of Tus-Holdings, Russian Direct Investment Fund, Tsinghua University, and Lomonosov Moscow State University. The purpose of this Innovation Complex is to prepare for future joint research and development centers, university labs for basic research, and science parks. This project followed the establishment in 2016 of the first Sino-Russian university founded by Beijing Institute of Technology, Shenzhen Municipal Peoples Government, and Lomonosov Moscow State University.[7] The new universitys mission is to to nurture talents for the Belt and Road Initiative.[8] Few joint research centers, for instance, in computational mathematics and cybernetics, were launched, and there are plans to open other centers in chemistry and materials, biology, and space science.[9]

In addition, the Russia-China Investment Fund, in partnership with Tus-Holdings, supports the construction of the Sino-Russian High-Tech Innovation Park at the Skolkovo Innovation Centre. According to the press release, Tus-Holdings is considering the possibility to create a network of innovation facilities in Russia by building new technology parks in other areas of the country.[10] Another science and technology park within Lomonosov Moscow State University is anticipated and is expected to become a platform for innovative cooperation between scientific and technological workers and scientific and technological enterprises of the two countries.[11]

These projects are recent, and at the moment, it is unclear whether they would be successful in spurring actual innovation in the near future. What is clear, though, is that their proliferation in the last few years signals the commitment to closer and long-term integration of the Russian and Chinese innovation systems. Such integration is incremental and might take decades. In the words of Tus-Holdings Chairman Jiwu Wang, the companys vision is an ecosystem of innovative cooperation in science and technology between China and Russia . . . and deepening economic integration between the two countries [emphasis added].[12]

(sputnikvaccine.com)

Chinese-Russian technological alignment has been particularly apparent in the sector of biotechnology. Broadly, biotechnology refers to the manipulation of living organisms or their compounds to produce new products or services. Biotechnology is perceived to be a key strategic technology for industrial growth and is distinguished from other technological sectors for its capacity to alter the means of production across a variety of industrial sectors.[13] Examples of the sectors include pharmaceuticals, agriculture, and food processing, and extend to dual-use technologies.

Biotechnology is a strategic sector for China. The Made in China 2025 Initiative sets the goal of manufacturing high-tech products, including innovative medicines.[14] The plan introduced targets for Chinese pharmaceutical firms to advance in biotechnology innovation and increase exports.[15] About half of all industrial parks in China focus on the development of pharmaceuticals.[16] By 2018, China established 111 biotechnology science parks.[17] Although China still lags behind the U.S. in biotechnology innovation, analysts concede that it is rapidly progressing and closing this gap.[18] So far, Chinas efforts have concentrated on creating the necessary infrastructure for biotechnology development.

In turn, Russia has rich natural resources, but over 80% of biotech products are imported, and Russias share in the global market of biotech products is below 0.1%.[19] Russian biotech is a sector that experienced massive brain drain after the break-up of the Soviet Union, with many scientists leaving for Western countries and Israel.[20] The persistent challenge for the Russian biotechnology industry, including the biopharmaceutical industry, is its critical dependency on imports. Between 1992 and 2014, the production of substances (active pharmaceutical ingredients) decreased by a factor of 20.[21] According to the Ministry of Industrial Policy of Russia, in 2015, the country imported 95% of active pharmaceutical ingredients required to produce finished pharmaceuticals.[22] In 2018, the share of foreign medicines on the Russian market constituted 70.2% by value and 39.4% by volume. In 2019, foreign medicines generated USD 19.6 billion in income, which was about 70% of the Russian pharmaceutical market.[23] By some accounts, this sum is larger than what Russia earns from its arms export.[24] Pharmaceutical imports exceed exports by 14 times.[25] By all formal indicators in life-science research and biotechnology, such as gross domestic product (GDP) expenditure on R&D, patents, and journal publications, Russia lags behind the United States, China, France, South Korea, Japan, Germany, and India.[26]

Yet, Russia sees biotechnology as a priority area for its future.[27] The first post-Soviet strategic document in this area was enacted in 2012 and entitled the State Coordination Program for the Development of Biotechnology in the Russian Federation until 2020 (BIO 2020). Around USD 18 million was invested in the development of biotechnology, with 22% directed to biomedicine and biopharmaceuticals research.[28] The results of the program are considered limited, except for some improvement in vaccine and monoclonal antibodies research.[29] The state programs in the pharmaceutical industry appear to be more specific and thus more practical.

For example, the State Program for the Development of the Pharmaceutical and Medical Industry until 2020 (PHARMA 2020), published in 2014, attempted to reduce Russias dependency on foreign medical technologies. Sanctions put added pressure on import substitution in this area.[30] As a result of this program, 50 new industrial sites were built, 130 new medicines entered the market (9 of which were classified as innovative), and 8 scientific-research centers of pre-clinical development were built or reconstructed.[31] In addition, PHARMA 2020 launched several biopharmaceutical projects, including those of Biocad and Generium,[32] some of the largest producers of the Sputnik V vaccine.[33]

Moscow approved PHARMA 2030 in December 2021. The main difference between PHARMA 2020 and PHARMA 2030 is a call for an upgrade from import substitution to an innovative model of production. In nine years, Russia aims to double the production of local medicines and medical equipment and increase their export. The program foresees investment in infrastructure to allow for deepening cooperation between production, science, and education.[34]

According to data from the Eurasian Economic Commission, Russias innovative companies include few active players: Generium, ChemRar, Biocad, and Pharmapark.[35] ChemRar, a high-tech center in the Moscow region, hosts a handful companies benefiting from its infrastructure and scientific-research institute. One of the objectives of the center is conducting R&D for its partners especially around innovative antibiotics. In 2020, ChemRar, with the help of the Russian Direct Investment Fund (RDIF), developed a specific medicine for anti-coronavirus treatment, Avifavir, which is currently supplied to 15 countries.[36] Avifavir is based on a known substance Favipiravir, originally developed in Japan to treat influenza, but ChemRar conducted clinical trials to confirm its effectiveness in treating COVID-19 specifically. Pharmapark, another Moscow-based company, is Russias top producer of the active pharmaceutical ingredient interferon alfa-2b and covers 80% of local demand of Russian producers of finished pharmaceuticals. Some of these companies are becoming instrumental in Sino-Russian biotech partnership.

When it comes to breakthroughs, what is notable about the Russian biopharma industry is the persistent Soviet legacy of production being subordinated to research institutes. By estimates, about 30 universities, mostly in Moscow and Saint Petersburg, have programs in biotechnology, and about 50 institutes of the Russian Academy of Science conduct biology research.[37] Consider the Russian COVID-19 vaccines as an example. The Sputnik V vaccine came out from the Gamaleya Institute, a state-owned research institute, not from industry. The Novosibirsk-based state-owned scientific center, Vektor State Research Center of Virology and Biotechnology, developed the EpiVacCorona vaccine.[38] Similarly, state-owned Chumakov Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences developed the KoviVac vaccine.[39]

(sputnikvaccine.com)

Arguably, Russias weak point is not in the development of biopharmaceutical innovation but in scaling-up of production. In the biotechnology sector, innovative projects are financially supported through Russian development institutes, such as Skolkovo, Russian Venture Company, and Rusnano.[40] Often, their resources only suffice for the development stage but not for substantially increasing production. For the latter, the Russian Foreign Direct Investment Fund plays a bigger role, but it would be limited without help from its international partners. This is where Chinas resources find a good application.

Notwithstanding the respective limitations of national biotech industries, Russia and Chinas cooperation has recently intensified and involved the use of the joint innovation infrastructure projects mentioned above. For example, Russian company Biocad,[41] together with Chinese manufacturer Shanghai Pharmaceuticals Holding (SPH), created a joint venture, SPH Biocad, based in China. SPH Biocad will commercialize Biocads portfolio of medicines (e.g., oncology and autoimmune treatment) in the Chinese market.[42] The joint venture received USD 400 million in funding, in which SPH holds 50.1% and Biocad 49.9%.[43] The long-term plan is to turn the joint venture from a generic producer into an innovative player.[44]

Another example of the use of the joint innovation infrastructure to advance biopharmaceutical cooperation is the Russia-China Investment Fund. In 2020, it invested in the creation of the Russian pharmaceutical holding Binnopharm Group.[45] In the same year, Binnopharm Group joined a group of companies involved in the production of the Sputnik V vaccine. With consolidated assets, Binnopharm Group became one of the top three largest pharmaceutical manufacturers in Russia and now owns the portfolio of over 450 registered medicines, the most among Russian companies.[46] Binnopharm Group plans to establish a new R&D center in Krasnogorsk (Moscow region) by integrating R&D centers of the enterprises that were merged and invest USD 33 million in the development of 100 new medicines by 2025.[47] The impact on biopharmaceutical innovation of this merger is yet to be seen. Evidently though, China has been behind the major projects aiming to help Russia create and improve the necessary infrastructure for the development of biopharmaceuticals industry. Infrastructure for innovation-based industries, such as biotechnology, is a key pillar, and Chinas kind of investment in Russia is aimed to develop and upgrade the necessary innovation capabilities.

In addition to joint investments, China and Russia have launched bilateral research projects. The countries agreed to establish a joint laboratory for research on COVID-19. The National Fund of Natural Sciences of China and the Russian Fund of Fundamental Research will supervise the project.[48] In a similar vein, the Russian Vektor State Research Centre of Virology and Biotechnology have cooperated with the Ministry of Science and Technology of China on projects related to the human avian influenza (bird flu).[49] The exchange of vaccine technology and declarations to combine efforts in coronavirus research accelerated the formation of the institutional links between the Chinese and Russian innovation systems, especially in the biotechnology sector. It signals the countries commitment to an enduring innovation partnership.[50]

The processes addressed in this paper have been unfolding before the war in Ukraine. Western decoupling from China and Russia has been pushing the two countries towards deepening their cooperation. The accelerating Sino-Russian innovation cooperation projects confirm this assumption. While it can be premature to assess the levels of joint biopharmaceutical innovation, the implications of Chinas engagement with the Russian biotech are not trivial. The nature of this engagement goes beyond investment projects, aiming to strengthen the institutional links between research organizations, manufacturers, and sovereign funds of the two nations. After February 24, 2022, Western sanctions and companies fleeing Russia will force Moscow to seek deeper cooperation with China in high-tech sectors. Russian biotech is not a self-sufficient industry and requires international partnerships to develop. But Russia is now limited in who it can partner with. Given the past trajectory of joint innovation partnership, naturally, China is now Russias ultimate bet when it comes to biotechnology development. Russian biotech future is in Chinas hands. There are not currently signs that China will change its favorable position towards Russia; hence, Sino-Russian innovation partnerships will likely intensify.

[1] Samuel Bendett and Elsa Kania, A New Sino-Russian High-Tech Partnership, Australian Strategic Policy Institute, October 2019, https://www.aspi.org.au/report/new-sino-russian-high-tech-partnership.

[2] Richard E. Baldwin, The Great Convergence: Information Technology and the New Globalization (Cambridge, Massachusetts: The Belknap Press of Harvard University Press, 2016), p. 294.

[3] For more details, see, Svitlana Lebedenko, Russian Innovation in the Era of Patent Globalization, IIC International Review of Intellectual Property and Competition Law 53, no. 2 (2022): pp. 173-193.

[4] Desheng Cao, China, Russia Enhance Links in Sci-Tech Innovation, China Daily, November 2021, https://www.chinadaily.com.cn/a/202111/27/WS61a16e3ea310cdd39bc77dbd.html.

[5] A long-term project announced by the General Secretary Xi Jinping in 2013 and envisioned to be completed by 2049.

[6] Russia-China Investment Fund, http://rcif.com/. See also: Belt and Road Initiative, BRI Institutions, https://www.beltroad-initiative.com/institutions-and-mechanisms/.

[7] About the University: Brief, Shenzhen MSU-BIT University, https://en.smbu.edu.cn/About_the_University/Brief.htm.

[8] Ibid.

[9] Development Plan, Shenzhen MSU-BIT University, https://en.smbu.edu.cn/info/1035/1258.htm.

[10] Russian Direct Investment Fund, RCIF and Tus-Holdings expand comprehensive cooperation in the technology & innovation sector, September 11, 2018, https://rdif.ru/Eng_fullNews/3412/.

[11] RDIF, RCIF and Tus-Holdings agree to jointly establish innovation center at Lomonosov Moscow State University, April 26, 2019, https://rdif.ru/Eng_fullNews/4050/.

[12] Ibid.

[13] Susan Bartholomew, National Systems of Biotechnology Innovation: Complex Interdependence in the Global System, in Systems of Innovation: Growth, Competitiveness and Employment, ed. Charles Edquist and Maureen McKelvey, I (Cheltenham, UK; Northampton, MA, USA: Edward Elgar Publishing Limited, 2000), pp. 444-445.

[14] Rolf Schmid and Xin Xiong, Biotech in China Innovation, Politics, and Economics (Singapore: Jenny Stanford Publishing, 2021), p. 285.

[15] Adolfo Arranz, Made in China 2025: Beijing Bets on Biotech, South China Morning Post, October 2018, https://multimedia.scmp.com/news/china/article/2167415/china-2025-biotech/index.html?src=social.

[16] Chinas Biotech Parks Leveraging the Ecosystem for Success (Deloitte, May 2021), p. 2, https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/articles/pr-china-biotech-parks-leveraging-the-ecosystem-for-success.html.

[17] Ibid.

[18] For indicators and comparative statistics, see, Robert D. Atkinson, Chinas Biopharmaceutical Strategy: Challenge or Complement to U.S. Industry Competitiveness? (Information Technology and Innovation Foundation, August 2019), https://itif.org/publications/2019/08/12/chinas-biopharmaceutical-strategy-challenge-or-complement-us-industry.

[19] Anna Grebenyuk and Nikolai Ravin, The Long-Term Development of Russian Biotech Sector, Foresight 19, no. 5 (September 2017): pp. 491, 498.

[20] Gigi Kwik Gronvall and Brittany Bland, Life-Science Research and Biosecurity Concerns in the Russian Federation, The Nonproliferation Review, February 2021, pp. 3-4.

[21] Vladimir V. Moiseev, State Policy of Economic Development of Modern Russia (2000-2016) (translation by author) (Moscow: Direkt-Media, 2017), p. 297.

[22] Information on the Results of Analysis of the State and Development of the Biotechnology Industry of Member States of the Eurasian Economic Union Working Materials (Translation by Author), (Moscow: Eurasian Economic Commission, Department of Industrial Policy, 2015), p. 27.

[23] Balakin, Ayginin, and Ivashenko, Russian Pharmaceutical Industry until 2030: Analytic Overview (Translation by Author), p. 38.

[24] Ibid.

[25] Aleksandr V. Evstratov, Main Tendencies and Ways of Development of the Pharmaceutical Market in the Russian Federation (translation by author) (Volgograd: VolgGTU, 2018), p. 18.

[26] Gronvall and Bland, p. 8.

[27] Ibid, p. 4.

[28] Ibid.

[29] Ibid.

[30] Arthur Boyarov, Alina Osmakova, and Vladimir Popov, Bioeconomy in Russia: Today and Tomorrow, New Biotechnology 60 (January 2021), p. 36.

[31] K.V. Balakin, A.A. Ayginin, and A.A. Ivashenko, Russian Pharmaceutical Industry until 2030: Analytic Overview (Translation by Author) (Dolgoprudny: Biopharmaceutical Claster Severnyi, 2021), pp. 42-43.

[32] Boyarov, Osmakova, and Popov, Bioeconomy in Russia, p. 37.

[33] Russian company plans to produce 5-6 mln doses of Sputnik V per month in June-July, Tass, April 6, 2021, https://tass.com/economy/1274415; and The Sputnik V Manufacturer Will Produce 20 Million Doses of Vaccine Per Month (translation by author), Generium, June 5, 2016, https://www.generium.ru/about/press_center/Media_about_us/proizvoditel-sputnika-v-s-iyulya-nachnet-vypuskat-20-mln-doz-vaktsiny-v-mesyats/.

[34] Balakin, Ayginin, and Ivashenko, p. 43.

[35] Information on the Results of Analysis of the State and Development of the Biotechnology Industry of Member States of the Eurasian Economic Union Working Materials (Translation by Author), pp. 28-30.

[36] Russias Avifavir Coronavirus Drug Registered in Indonesia, Russian Direct Investment Fund, March 2021, https://rdif.ru/Eng_fullNews/6644/.

[37] Overview of the Biotechnology Market in Russia and of its Prospects of Development (translation by author) (Frost & Sullivan, 2014), p. 21.

[38] By December 2020, Vektor has also developed a vaccine against HIV and conducted the first phase of clinical trials. Balakin, Ayginin, and Ivashenko, Russian Pharmaceutical Industry until 2030: Analytic Overview (Translation by Author), pp. 41-42.

[39] Pharmaceutical Market of Russia 2020 (Translation by Author) (Moscow: DSM Group, 2020), p. 117.

[40] Overview of the Biotechnology Market in Russia and of its Prospects of Development (translation by author), p. 17.

[41] Biocad is a scientific-production company in the Moscow region with the focus on urology, gynecology, oncology, and neurology products.

[42] Ben Hargreaves, China and Russia Collaborate to Create Biologics Joint Venture, Bio-Pharma Reporter, October 2, 2019, https://www.biopharma-reporter.com/Article/2019/10/02/China-and-Russia-collaborate-to-create-biologics-JV.

[43] Ibid.

[44] Ibid.

[45] The Russian pharmaceutical company Alium was founded in 1994 on the basis of the Research Centre of Applied Microbiology. In 2019, it was acquired by JSC AFK Sistema. In 2020, all the pharmaceutical assets of the JSC AFK Sistema, including Alium, were merged in Binnopharm Group. See, Binnopharm Croup, https://binnopharmgroup.ru/.

[46] Morgan Lewis Advises the Russia-China Investment Fund (RCIF) on Creation of Pharmaceutical Holding, Chambers and Partners, February 2021, https://chambers.com/articles/morgan-lewis-advises-the-russia-china-investment-fund-rcif-on-creation-of-pharmaceutical-holding.

[47] Russias Binnopharm Group Hopes to Launch up to 100 New Drugs in Comin, ThePharmaLetter, September 2021, https://www.thepharmaletter.com/article/russia-s-binnopharm-group-hopes-to-launch-up-to-100-new-drugs-in-coming-years.

[48] Ibid.

[49] International Cooperation (Translation by Author), Russian Centre for Virology and Biotechnology Vektor, http://www.vector.nsc.ru/mejdunarodnoe-sotrudnichestvo/.

[50] See, for instance, a declaration of Xi Jinping on deepening the cooperation with Russia on vaccine development. Xi Eyes Deeper Vaccine Cooperation with Russia, Xinhuanet, August 2021, http://www.news.cn/english/2021-08/25/c_1310148390.htm.

Continued here:
The Rise of Sino-Russian Biotech Cooperation - Foreign Policy Research Institute

Appointment of Independent Director Adds to Financial Expertise on Board

Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (Curative Biotech or the Company), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoffhas participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies.Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.

About Cary Sucoff

Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm. Currently, Mr. Sucoff serves on the following Boards of Directors:

Contrafect Corp. - engaged in Phase 3 development of new treatments for infectious diseases utilizing proprietary antibody and lysin technology (Audit; Nom/Gov; Pricing).

IMAC Holdings - provides movement and orthopedic therapies and minimally invasive procedures performed through regenerative and rehabilitative medical treatments delivered in private clinics and facilities inside Walmart stores. (Audit; Nom/Gov; Comp).

Galimedix Therapeutics, Inc. - technology licensed from Tel Aviv University for potentially revolutionary treatments for Glaucoma and Dry Age-related Macular Degeneration (Audit; Nom/Gov).

First Wave Technologies, Inc. - new and innovative medical device technologies focused on anesthesia and ventilator technology (M&A).

In addition, Mr. Sucoff currently serves as an advisor to:

Sapience Therapeutics, Inc. - a Phase 1/2 Biotech company focusing on Glioblastoma.

LB Pharmaceuticals - a NY-based biotech company developing a Phase 2 novel drug to treat schizophrenia.

Kinetic Power Systems - an energy developer and manufacturer of long duration flywheel energy storage systems or mechanical batteries.

Mr. Sucoff, a former New York City prosecutor, is the Past President of New England Law/Boston (Boston, Ma.) and is the senior member of its Board of Trustees where he has served for over 30 years. He has been Chairman of the Endowment Committee for over 10 years and sits on the Finance Committee. Mr. Sucoff received a B.A. from SUNY Binghamton (1974) and a J.D. from New England School of Law (1977) where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.

Future Curative Biotechnology Press Releases and Updates

Interested investors and shareholders can be notified of future Press releases and Industry Updates by e-mailingir@curativebiotech.com

About Curative Biotechnology, Inc.http://curativebiotech.com

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Companys pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-lookingstatements are inherently subjected to known, unknown risks and uncertainties that may cause actualresults to be materially different from those discussed in these forward-looking statements, including butnot limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cashflow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financialcondition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact:

Steve ChizzikInvestor RelationsCurative Biotech (CUBT)201-454-5845ir@curativebiotech.com

Read this article:
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors - GlobeNewswire

Assistant Professor (or above) in Biotechnology or Biomedicine

Recruiter: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung UniversityAcademic Discipline: Biotechnology or BiomedicineJob Type: Assistant Professor, Associate Professor, or ProfessorExpected Starting Date: February 1st, 2023

Job Description

National Cheng Kung University (NCKU) is a prestigious university in Taiwan with strengths in Engineering, Sciences, Life Sciences, and Social Sciences. NCKU is a renowned academic and research institution that attracts numerous domestic and international talents. This post is offered under the Program on Bilingual Education for Students in College (BEST) of the Ministry of Education to build a more diverse and international environment for NCKUs students and you will be fully dedicated to conducting NCKUs bilingual education policies.

This post offers an exciting opportunity to make a contribution to the development of NCKUs EMI curriculum development and EMI teaching in the area of Biotechnology or Biomedicine. You will conduct bilingual education policies in the area of Biotechnology or Biomedicine, and enhance the quality of the educational environment in related areas in support of the Universitys continuing emphasis on international excellence. Before the end of each academic year, your working performance will be evaluated with consideration for renewing your contract.

Key Responsibilities

Essential Criteria

All applicants are asked to submit:

Please submit the documents mentioned below to the contact address and email PDF files to: fang@mail.ncku.edu.tw.* Regarding letters of recommendation, it is acceptable to only send them to us in paper form.

Submission Deadline:

June 1st, 2022. (Please state "Application for EMI teaching position" in the subject of the letter/ email.) Please note that we would not accept an overdue or incomplete application. We would invite suitable candidates to have an interview, and unsuitable ones documents would not be returned.

Contact:

Visit link:
Assistant Professor (or above) in Biotechnology or Biomedicine job with NATIONAL CHENG KUNG UNIVERSITY | 292647 - Times Higher Education

The study on Global Biotechnology Media, Sera and Reagents Market focuses on the analysis of the present trends in the global market. The objective of MarketsandResearch.biz is to provide a comprehensive view of the market to the clients and help them build growth strategies. The Biotechnology Media, Sera and Reagents provides a forecast for a period of 2022-2028 based on an in-depth and expert observation.

The document provides a detailed evaluation of main market players in the global Biotechnology Media, Sera and Reagents marketplace, consisting of product offerings, business overviews, nearby presence, business strategies, mergers & acquisitions, SWOT analysis, latest developments, and significant financial information.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/251130

The study has thoroughly examined crucial factors which include drivers and restraints, opportunities, production, market players, and competition. Important industry trends, market size, market proportion estimates, and profiles of the top industry competitors are all discussed on this document.

The income projection is based absolutely upon the modern performance of the phase.Report emphasis on assessment of nearby phase:

Report offers a granular evaluation of the market phase of the marketplace:

The segmentation analysis includes a descriptive assessment of the segments, presentation of the market stocks constituted by each section, increase rate of every section, and attractiveness of the segment in terms of revenue.

The producers worried in the marketplace include

Report offers a granular evaluation of the market phase of the market:

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/251130/global-biotechnology-media-sera-and-reagents-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2027

The report delves first into the foundation of the Biotechnology Media, Sera and Reagents by looking at definitions, categories, and market overview. This then further helps understand the various product specifications, supply chain, manufacturing process, and the cost structure and thus provide a depth in the understanding of the building blocks of this industry and understand the major drivers of change in it.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.biz

Visit link:
Global Biotechnology Media, Sera and Reagents Market 2022 Offered In New Research Forecast Through 2028 Queen Anne and Mangolia News - Queen Anne and...

James Campbell is pretty proud of the groundbreaking work he is involved in to help patients better battle cancer.

The CEO and managing director of the publicly listed company, Patrys Limited, is helping drive the development of a potential cancer drug that can cross the delicate blood-brain barrier, and help reduce tumour sizes and increase patient survival.

It's just one of the many potentially life-saving ideas and developments that some of Australia's brightest minds will be bringing to Albury for this week'sBioshares Biotech Summit.

While regional Australia is not often the first place people think of when it comes to biotechnology, Dr Campbell, who also sits on the board of Australia's biotechnology industry organisation AusBiotech, said it was where a lot of the action was happening.

"I think regional Australia is really important," he said.

"Biotech is not an industry many people think is amenable for being in the regions, but I think we have seen in the past few years that with the right approach, the right attitude, the right infrastructure and technology, folks can work from pretty much anywhere.

"Why wouldn't you work from regional Australia when we have so many advantages?

"You don't need to be in a capital city to really push some of these technologies along."

While the biotech ideasmay fly thick and fast, thesector is one that also requires a lot of patience.

It takes on average between 10 and 14 years, and a funding injection of about $2.5 billion, for an idea to be delivered to patients.

Much of this development relies on the backing of private investors.

It can take even longer for these treatments to reach patients in regional areas, despite some of the minds behind the groundbreaking developments working from there.

"What I'd say is it's always important for patients to be having that discussion with their doctors: 'Can we please try to get me enrolled in clinical trials?', even if that means trials in the capital cities," Dr Campbell said.

The CEO of Australian pharmaceutical company Amplia, John Lambert, is another leader who will be visiting Albury for the conference.

Dr Lambert's teamis working on an experimental treatment that attacks tumours thathave built up a strong resistance to the immune system and chemotherapy and are difficult to treat, including those in the pancreas and ovaries.

The company's experimental drug aims to disrupt the protective barrier around those tumours and enhance the effectiveness of cancer treatment.

It's another exciting project happening in the biotech sphere and an example of one that could potentially be developed in regional areas if the right infrastructure wasin place.

"A large regional hospital that has access to adequate facilities and a number of patients go there for treatment would be a real magnet," Dr Lambertsaid.

But for now, the majority of the trials that need to be conducted in controlled clinical environments remain in major cities.

"Being from the city, we recognise the inconvenience and disruption that people participating in clinical trials, and for that matter even getting routine treatment for people with serious illness, can encounter," Dr Lambert said.

"The trial our company is about to commence will initiate recruiting people who do live in larger state capitalsbut, as we expand the trial if we see early signs of success, we would hope to push the trial into regional centres, and if the drug is approved it would be available for everyone.

"People in the regions need treatment just as much as everyone else, and they have the additional burden of having to travel often to get that treatment."

Posted9 May 20229 May 2022Mon 9 May 2022 at 5:52am, updated9 May 20229 May 2022Mon 9 May 2022 at 8:04pm

View post:
Biotechnology brains flock to regional Australia, but trials still based in metro areas - ABC News

You should read the following discussion and analysis of our financial conditionand results of operations together with our unaudited condensed consolidatedfinancial statements and the related notes included elsewhere in this QuarterlyReport and our audited consolidated financial statements and notes thereto andthe related Management's Discussion and Analysis of Financial Condition andResults of Operations included as part of our Annual Report on Form 10-K asfiled with the SEC on March 16, 2022 (2021 Annual Report). This discussion andanalysis and other parts of this Quarterly Report contain forward-lookingstatements that are based upon current beliefs, plans and expectations relatedto future events and our future financial performance that involve risks,uncertainties, and assumptions, such as statements regarding our intentions,plans, objectives, and expectations for our business. Our actual results and thetiming of selected events could differ materially from those described in orimplied by these forward-looking statements as a result of numerous factors,including those set forth in the section titled "Risk Factors." See also thesection titled "Special Note Regarding Forward-Looking Statements."

Overview

range of therapeutic areas. We are in the early stages of development across abroad pipeline of product candidates, all of which are currently in thepreclinical stage of development and are summarized below:

COVID-19 business update

Acquisitions

License and collaboration agreements

Success payments and contingent consideration

Cobalt success payment and contingent consideration

Components of operating results

Operating expenses

Research and development

Research and development related success payments and contingent consideration

General and administrative

Results of operations

Comparison of the three months ended March 31, 2022 and 2021

Research and development expenses

The following table summarizes the components of our research and developmentexpenses for the periods presented:

$ 41,880 $ 30,809

an increase of $11.2 million in personnel-related expenses, including an

increase in non-cash stock-based compensation of $3.0 million, which was

an increase of $9.1 million in research, development, and laboratory

costs, including third-party manufacturing costs, laboratory supplies, and

other external research expenses;

an increase of $5.3 million in facility and allocated costs, including

an increase of $4.9 million related to licensing technology for our CD22

and BCMA programs.

Research and development related success payments and contingent consideration

$ 127,050 $ (182,488 )

General and administrative Expenses

Liquidity, capital resources, and capital requirements

Sources of liquidity

Future funding requirements

Our future capital requirements will depend on many factors, including:

the scope, timing, progress, costs, and results of discovery, preclinical

the number and scope of clinical trials required for regulatory approval

of our current or future product candidates;

the costs, timing, and outcome of regulatory review of our current or

future product candidates;

the cost associated with building our manufacturing capabilities, as well

as costs associated with the manufacturing of clinical and commercial

supplies of our current and future product candidates;

the costs and timing of future commercialization activities, including

manufacturing, marketing, sales, and distribution, for any of our product

applications, maintaining and enforcing our intellectual property rights,

and defending any intellectual property-related claims, including any

claims by third parties that we are infringing upon their intellectual

collaborations, licensing, or other arrangements and the financial terms

of any such agreements, including the timing and amount of any future

milestone, royalty, or other payments due under any such agreement;

the revenue, if any, received from commercial sales of our product

our ability to establish a commercially viable pricing structure and

obtain approval for coverage and adequate reimbursement from third-party

and government payors;

potential interruptions or delays resulting from factors related to the

the extent to which we acquire or invest in businesses, products, and

technologies.

Cash flows

The following table summarizes our cash flows for the periods indicated:

Financing activities

Contractual obligations and commitments

The following table summarizes our significant contractual obligations andcommitments as of March 31, 2022:

Off-balance sheet arrangements

Since our inception, we have not engaged in any off-balance sheet arrangementsas defined under the rules and regulations of the SEC.

JOBS Act accounting election

Critical accounting policies and significant judgements and estimates

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Originally posted here:
SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

BioNEST caters to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance

BioNEST caters to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance

A Bioincubators Nurturing Entrepreneurship for Scaling Technologies (BioNEST) facility was inaugurated at Manipal Academy of Higher Education (MAHE) in Manipal, Udupi district of Karnataka, on April 29.

BioNEST is supported by Biotechnology Industry Research Assistance Council (BIRAC) of the Department of Biotechnology. BioNEST is a dedicated scheme of BIRAC that supports the creation of globally competent bioincubation facilities across India. The scheme supports specialised incubation centres to cater to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance. This scheme is aligned with national mission programmes such as Startup India and Make in India.

The facility at MAHE promotes technology innovations for the development of knowledge-based enterprise with successful business models. Bioincubator provides world class faculty, infrastructure and services for incubation of start-ups in various domains of biopharma, biomedical devices, dental innovation, biotechnology, healthcare and diagnostics sectors.

The facility is spread over 10,000 sq. ft. and located at the heart of MAHE. it consists of dedicated and shared laboratories, offices, well-equipped instrumentation electronics testing facility, FAB laboratories, microfluidic laboratory, co-working space, office spaces, board room, meeting rooms, cafeteria and other amenities.

In addition, MAHE supports incubates with access to central equipment facilities, mentors and experts. BioNEST provide various services in technology management, IP management, technology transfer, business plan development, prototype development, refinement, grants support assistance and market evaluation of innovative technology ideas.

The facility was inaugurated by Ranjan R Pai, Chairman, Manipal Education and Medical Group (MEMG), Bengaluru during an event attended by Manish Diwan, DGM & Head - Strategy Partnership & Entrepreneurship Development, BIRAC, Delhi; H. S. Ballal, Pro Chancellor, MAHE, and M. D. Venkatesh, Vice Chancellor.

Visit link:
BioNEST facility opened at MAHE in Manipal for biotechnology start-ups - The Hindu

Biotechnology is a wide discipline that harnesses cellular and biomolecular processes to develop technologies that help in improving the health and lives of the people.

Biotechnology is the field that exploits living organisms to make technological advances in various fields for the sustainable development of mankind. It has its applications in the medical as well as agricultural sectors. The biological processes of living organisms have been used for more than 6000 years to make essential products such as bread, cheese, alcohol, etc.

Let us have a look at the various types and applications of biotechnology in various fields.

Also Read: Biotechnology Principles

Biotechnology is divided into the following types:

Medical biotechnology involves the use of living cells to develop technologies for the improvement of human health. It involves the use of these tools to find more efficient ways of maintaining human health. It also helps in the study of DNA to identify the causes of genetic disorders and methods to cure them.

Vaccines and antibiotics have been developed with the help of medical biotechnology that is essential for human health. Several plants are genetically engineered to produce antibodies with the help of biotechnology.

This field deals with the development of genetically modified plants by introducing the gene of interest in the plant. This, in turn, helps in increasing the crop yield.

Various pest-resistant crops such as Bt-cotton and Bt-brinjal are created by transferring the genes from Bacillus thuringiensis into the plants.

The animals with the most desirable characteristics are bred together to obtain the offspring with the desired traits.

Also Read: Biotechnology Principles and Processes

Following are the important applications of biotechnology:

Nutrients can be infused into food in situations of aid. e.g., Golden rice is prepared by the infusion of beta-carotene into the rice.

Biotechnology helps in the production of crops that can handle abiotic stress such as cold, drought, salinity, etc. In the regions with extreme climatic conditions, such crops have proved beneficial in withstanding the harsh climate.

Biotechnology involves the production of alcohol, detergents, cosmetic products, etc. It involves the production of biological elements and cellular structures for numerous purposes.

Spider webs have materials with the strongest tensile strength. The genes from the spiders have been picked up through biotechnological techniques and infused in goats to produce silk proteins in their milk. This helps in the production of silk easily.

Biotechnology is widely used in energy production. Due to the depletion of natural resources, there is a need to find an alternative source. Such fuels are produced by using biotechnology tools. These are environment friendly and do not release any greenhouse gas.

Biotechnology is applied in the development of pharmaceuticals that had proven problematic when produced through conventional means due to purity concerns.

Also Read: Applications Of Biotechnology

This is how biotechnology is a boon to society. To know more about biotechnology class 12 topics such as what is biotechnology, its types and applications, keep visiting BYJUS website or download BYJUS app for further reference.

See original here:
Biotechnology - Types And Applications Of Biotechnology